Moss Genomics Secures $250,000 Through Private Placement and Acquires 160 ETH

Moss Genomics Announces Private Placement Closing, 160 Ethereum Acquisition And Adds Hunter Jordan To Board Of Directors

  • Moss Genomics completes private placement raising $250,000 through issuance of 2.5 million shares at $0.10 each.
  • Company acquires 160 Ethereum cryptocurrency through issuance of 7.84 million common shares.
  • Hunter Jordan, a real estate investment executive with CPA background, joins the Board of Directors.
  • Company grants 200,000 stock options to directors, officers, and consultants at $0.20 exercise price.
  • Strategic move combines biotechnology with blockchain treasury management.

Moss Genomics Inc. (CSE: MOSS) (FSE: F73) has completed a dual-track expansion, securing traditional equity financing while simultaneously advancing into the cryptocurrency space through a significant Ethereum acquisition.

- Advertisement -

The biotechnology company’s private placement generated $250,000 through the issuance of 2.5 million common shares priced at $0.10 each. In a parallel move, Moss acquired 160 ETH by issuing 7.84 million common shares, marking a significant entry into cryptocurrency treasury management.

Hunter Jordan, newly appointed to the company’s Board of Directors, brings strategic oversight from his position as VP at a private real estate firm. His appointment strengthens Moss’s governance structure as it navigates the intersection of biotechnology and blockchain technology.

The company’s innovative approach combines Artificial Intelligence and genomic research with blockchain integration, representing a novel convergence in the life sciences sector. To incentivize leadership, Moss granted 200,000 stock options to key personnel, exercisable at $0.20 per share over five years.

These developments are subject to Canadian Securities Exchange final acceptance, with securities under a standard four-month-plus-one-day holding period. The company plans to utilize proceeds from both transactions for working capital purposes, advancing its unique position in the biotechnology-blockchain nexus.

- Advertisement -

For U.S. investors, these securities remain unregistered under the U.S. Securities Act, with trading restricted to non-U.S. persons unless qualifying for exemption status.

✅ Follow BITNEWSBOT on Telegram, Facebook, LinkedIn, X.com, and Google News for instant updates.

Previous Articles:

- Advertisement -

Latest News

Cloudflare Unveils NET Dollar Stablecoin for AI-Driven Web

Cloudflare plans to launch a U.S. dollar-pegged stablecoin called NET Dollar for use on...

Radix Resumes Multi-Factor Recovery Rollout With 3-Phase Plan

Radix will restart development on native on-chain multi-factor authentication (MFA) for its wallet, following...

Critical ‘ForcedLeak’ Flaw Hits Salesforce Agentforce AI System

A critical vulnerability, named ForcedLeak, has been discovered in Salesforce’s Agentforce AI platform. The flaw...

Russell 2000 Hits Record, Sparking Hopes for New Crypto Altseason

Investors are watching for signs of an altseason, a period when altcoins surge in...

Silver Surges Amid Growing Retail Interest, Eyes $100 per Ounce Mark

Precious metals such as silver are experiencing notable price movement, drawing increased attention from...
- Advertisement -

Must Read

10 Best Crypto Audiobooks You Don’t Want to Miss

So, you are getting tired of reading books and you want to switch to audiobooks that talk about cryptocurrencies. Well, today we are going...